BAUSCH + LOMB ANNOUNCES STATISTICALLY SIGNIFICANT TOPLINE RESULTS FROM THE FIRST PHASE 3 TRIAL OF NOV03 (PERFLUOROHEXYLOCTANE) IN DRY EYE DISEASE ASSOCIATED WITH MEIBOMIAN GLAND DYSFUNCTION
All Primary and Secondary Endpoints Were Achieved
Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc. (“Bausch Health” or the “Company”), and Novaliq GmbH, a biopharmaceutical company focusing on first- and best-in-class ocular therapeutics, today announced statistically significant topline data from the first Phase 3 trial (GOBI trial) evaluating the investigational drug NOV03 (perfluorohexyloctane) as a first-in-class eye drop with a novel mechanism of action to treat the signs and symptoms of dry eye disease (DED) associated with meibomian gland dysfunction (MGD).